Featured Research

from universities, journals, and other organizations

Lymphoma and leukemia discovery may improve therapy

Date:
November 1, 2010
Source:
Institut de recherches cliniques de Montreal
Summary:
Scientists have identified a mechanism regulating activation-induced deaminase, which could be important for the therapy of some types of lymphoma and leukemia.

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montrιal (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published November 1 by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

AID is a B-lymphocyte enzyme that creates deliberate mutations in the DNA encoding antibodies, which helps produce an appropriate immune response. However, inappropriate expression of AID can also have harmful effects and lead to certain oncogenic (cancer-causing) mutations. When found in a tumour, uncontrolled levels of AID could increase the rate of gene mutation and, in turn, accelerate the progression of the disease.

"In studying the regulation of AID, we attempted to understand what restricts its access to the cell's nucleus," explains Alexandre Orthwein, doctoral student in Dr. Di Noia's research unit and first author of this study. "If we could control that aspect, we could prevent AID's negative mutating effects. We then discovered that Hsp90, one of the most abundant and vital proteins found in cells, stabilizes AID in the cytoplasm. Cytoplasmic AID is in fact in a dynamic equilibrium regulated by Hsp90."

By stabilizing AID, Hsp90 determines the enzyme's overall expression levels, which correlate with the extent of its physiological functions. Hence, Hsp90 assists AID-mediated antibody diversification. A number of Hsp90 inhibitors being commercially available, the researchers found that Hsp90 inhibition destabilizes AID, thus resulting in a proportional reduction in antibody gene diversification. Moreover, since AID levels also correlate with its pathological side effects, Hsp90 inhibition prevents uncontrolled off-target mutation by AID.

"We showed that inhibiting Hsp90 with known drugs, which are also currently used in clinical trials for the treatment of certain cancers, significantly reduces the amount of AID and, consequently, prevents this enzyme's undesired activity on DNA," adds Dr. Di Noia. "This regulatory mechanism determines the functional levels of AID in normal B cells and B cell lymphoma lines. So, Hsp90 inhibition provides the first pharmacological means to regulate AID expression and activity, which could be relevant for the therapy of some types of lymphoma and leukemia."

Dr. Di Noia, along with the IRCM's Technology Transfer Office, is currently taking the necessary steps to patent the proposed application of the Hsp90 inhibitors with the Canadian Intellectual Property Office (CIPO) and the United States Patent and Trademark Office (USPTO). These patent applications, promoted and commercialized by Univalor, cover the use of the AID biomarker in the selection of a cancer-fighting therapy. In the context of this technology, the treatment using an Hsp90 inhibitor targets tumours expressing AID, and consists of the administration of predetermined doses of the inhibitor in accordance with the expression levels of AID in the tumours.

According to The Leukemia & Lymphoma Society of Canada, one person is diagnosed with a blood cancer every four minutes and someone dies from a blood cancer every 10 minutes. This statistic represents over 54,000 people per year. In 2010, about 628,415 people are living with lymphoma or are in remission.

This research project was supported by the Canadian Institutes of Health Research (CIHR).

Other researchers contributed to the study, including Anne-Marie Patenaude, research assistant in Dr. Di Noia's laboratory, El Bachir Affar from the Hτpital Maisonneuve-Rosemont, Alain Lamarre from the INRS-Institut Armand-Frappier research centre, and Jason C. Young from McGill University.


Story Source:

The above story is based on materials provided by Institut de recherches cliniques de Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alexandre Orthwein, Anne-Marie Patenaude, El Bachir Affar, Alain Lamarre, Jason C. Young and Javier M. Di Noia. Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90. The Journal of Experimental Medicine, 2010 DOI: 10.1084/jem.20101321

Cite This Page:

Institut de recherches cliniques de Montreal. "Lymphoma and leukemia discovery may improve therapy." ScienceDaily. ScienceDaily, 1 November 2010. <www.sciencedaily.com/releases/2010/11/101101131648.htm>.
Institut de recherches cliniques de Montreal. (2010, November 1). Lymphoma and leukemia discovery may improve therapy. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2010/11/101101131648.htm
Institut de recherches cliniques de Montreal. "Lymphoma and leukemia discovery may improve therapy." ScienceDaily. www.sciencedaily.com/releases/2010/11/101101131648.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) — A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) — A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) — A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) — Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins